JUVA Driving Revenue, PACE is PICKING UP !! Already Driving Revenue - And the Pace is Picking Up
With their new database set to open new opportunities, Juva Life ( CSE: JUVA ; OTC: JUVAF ) has also been busy driving revenue through the other arm of their business.
While it usually costs over $2 billion to develop new treatments the old way through the FDA...
They are aiming to cut years, billions of dollars, and lots of risk out of the process because of the IRB-approved processes they can conduct their research through.
And they plan to fund this database in part through their other verticals, which are already bringing in revenue with paying customers. Do your DD.